Transparency Market Research
MDD, Anxiety and Panic Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Single User License: USD 4315.5
Flat 10% Discount!! Free Customization as per your requirement You will get Custom Report at Syndicated Report price Report will be delivered with in 15-20 working days
Request Sample
Buy Now
REPORT DESCRIPTION
Transparency Market Research Reports incorporated a definite business overview and investigation inclines on “MDD, Anxiety and Panic Disorder Therapeutics Market�. This report likewise incorporates more illumination about fundamental review of the business including definitions, requisitions and worldwide business sector industry structure. Epidemiologic studies have concluded that majority of the individuals experiencing panic attack will also experience a major depression disorder (MDD) and this factor increases the possibility of co-occurrence of panic disorder. These disorders tend in functional disability along with suicidal behavior in the patients and are in association with depression and panic conditions. Anxiety symptoms include obsessive, obtrusive, worried thoughts, irritability, confusion and difficulty concentrating and frustration. Person with anxiety also feel uncomfortable physical sensations, tense some characteristics such as trembling, a racing heartbeat, sweating, difficulty breathing and nausea. The sudden onset of such symptoms is often an indicator of a severe panic attack. Anxiety can also lead to lightheadedness, headaches, digestive problems and insomnia. Browse Full Report with TOC: http://www.transparencymarketresearch.com/mdd-anxiety-panic-disorder-therapeutics.html According to National Comorbidity Survey Replication, the prevalence for an anxiety disorder was about 18%, and for mood disorder it was 9.5% every year. Lifetime prevalence for any anxiety disorder and MDD were approximately 29% and 16.6%, respectively. Assuming a 50% comorbidity rate, between 5% and 9% of the adult population has comorbid depression-anxiety in a year’s time. The treatment against these comorbid depression and anxiety disorder are cognitive-behavioral therapy (CBT) as an effective psychological treatment but it needs support from therapeutic drugs where anti-depressants are observed to be the first-line of treatment for comorbid depression and anxiety disorders. But in this disorder the anti-depressants may turn into panic attacks for patients when they have undetected bipolar disorder which should be analyzed by mapping the family history of patient before treatment. According to World Health Organization (WHO), neuropsychiatric disorders accounted for more than 13% of all medical disability worldwide and for more than 27% of all
noncommunicable disease in 2005. Depression alone produced 10% to 12% of all disability from noncommunicable disease and approximately 5% of all disability (noncommunicable, communicable, injury). Thus, comorbid anxiety and depression may account for as much as 2% to 4% of all medical disability worldwide. The antidepressants particularly used in this treatment are serotoninspecific reuptake inhibitor (SSRI) such as escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, sertraline and Serotoninnorepinephrine reuptake inhibitors (SNRI) is venlafaxine that are observed to be the first-line pharmacotherapy for depression and anxiety disorders. The recent updates regarding major depression disorder (MDD), anxiety and panic disorder market is about to go through a vibrant phase with forthcoming patent expiries for leading products such as BMS/Otsuka’s Abilify and Eli Lilly's Cymbalta, and in January 2014 the recent launch of, Lundbeck/Takeda's Brintellix a multimodal antidepressant. The other devices present in the pipeline are Richter/Mitsubishi Tanabe Pharma’s cariprazine, Naurex’s GLYX-13, Forest (Actavis)/Gedeon and Alkermes’s ALKS-5461 along with antidepressant therapies such as Lundbeck/Takeda’s tedatioxetine, e-Therapeutics’ ETS6103 and Euthymics Bioscience’s amitifadine. The overall major depression disorder (MDD), anxiety and panic disorder market is about to observe a significant growth in the market. As the drivers impacting this market are primarily increasing the amount of stress and lack of sleep in adult population that are having various psychological problems. Some of the key players in the Major Depression Disorder (MDD), anxiety and panic disorder market are Shire Plc, Forest Laboratories, Novartis AG, Astra Zeneca Plc, Eli Lilly and Company, Pfizer, Inc., Janssen Pharmaceuticals, Inc. (JPI), BTG International (BTG), H. Lundbeck A/S, Alexza Pharmaceuticals and others. Read More Reports on Pharmaceutical Markets: http://www.transparencymarketresearch.com/pharmaceutical-market-reports1.html This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
North America
Asia Pacific
Europe
Rest of the World
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis. Enquiry before Buying @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928 About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.
Followed LinkedIn :-https://www.linkedin.com/today/post/article/20140807054413-349336221-mdd-anxiety-and-panic-disordertherapeutics-market Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY —12207 United States Tel: +1-518-618-1030 USA —Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com/ Website: http://www.transparencymarketresearch.com/ Browse Market Research Blogs: http://researchreportsindustry.wordpress.com/ http://marketingfirmblog.wordpress.com/